← Browse by Condition
Medical Condition

advanced pancreatic cancer

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, EARLY_Phase 1

Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.

Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.

The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.

Frequently Asked Questions — advanced pancreatic cancer Clinical Trials

How many clinical trials are currently recruiting for advanced pancreatic cancer?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for advanced pancreatic cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced pancreatic cancer?
advanced pancreatic cancer research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced pancreatic cancer clinical trial?
Eligibility criteria for advanced pancreatic cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Centre Leon Berard 1 trial
Hangzhou Converd Co., Ltd. 1 trial
Hainan Cancer Hospital 1 trial

Recruiting Clinical Trials

NCT05380414
Recruiting

Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients

Enrollment
750 pts
Location
France
Sponsor
Centre Leon Berard
View Trial →
NCT07006077 Phase 2
Recruiting

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

Enrollment
12 pts
Location
China
Sponsor
Hangzhou Converd Co., Ltd.
View Trial →
NCT07416240 EARLY_Phase 1
Recruiting

Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.

Enrollment
10 pts
Location
China
Sponsor
Hainan Cancer Hospital
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology